Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MSD first company to receive recommendation for drug based on PIP

This article was originally published in SRA

Executive Summary

The antifungal drug Cancidas has become the first medicine to be recommended by the European Medicines Agency (EMEA) for use in children, based on clinical trial data, generated in accordance with an agreed paediatric investigation plan (PIP). The agency’s Committee for Medicinal Products for Human Use (CHMP) recently concluded that the data on the quality, safety and efficacy presented support to an extension of indication for paediatric use.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS108533

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel